Immunovant, Inc.

NasdaqGS:IMVT Stock Report

Market Cap: US$3.6b

Immunovant Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:IMVT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Nov 24SellUS$106,228Eva BarnettIndividual4,174US$25.45
20 Nov 24SellUS$85,334William MaciasIndividual3,353US$25.45
20 Nov 24SellUS$424,811Peter SalzmannIndividual16,692US$25.45
20 Nov 24SellUS$92,893Mark LevineIndividual3,650US$25.45
23 Oct 24SellUS$80,912Jay StoutIndividual2,740US$29.53
23 Oct 24SellUS$94,171Michael GeffnerIndividual3,189US$29.53
23 Oct 24SellUS$128,780Mark LevineIndividual4,361US$29.53
16 Oct 24SellUS$94,172Eva BarnettIndividual3,271US$28.79
16 Oct 24SellUS$91,783William MaciasIndividual3,188US$28.79
16 Oct 24SellUS$82,339Mark LevineIndividual2,860US$28.79
16 Oct 24SellUS$261,845Peter SalzmannIndividual9,095US$28.79
09 Oct 24SellUS$131,838Peter SalzmannIndividual4,460US$29.56
09 Oct 24SellUS$152,589Eva BarnettIndividual5,162US$29.56
21 Aug 24SellUS$480,052Peter SalzmannIndividual15,068US$32.32
21 Aug 24SellUS$120,045Eva BarnettIndividual3,768US$32.32
21 Aug 24SellUS$96,437Julia ButchkoIndividual3,027US$32.32
21 Aug 24SellUS$96,437William MaciasIndividual3,027US$32.32
21 Aug 24SellUS$104,976Mark LevineIndividual3,295US$32.32
24 Jul 24SellUS$111,456Mark LevineIndividual4,015US$27.76
24 Jul 24SellUS$95,939Michael GeffnerIndividual3,456US$27.76
24 Jul 24SellUS$78,089Jay StoutIndividual2,813US$27.76
17 Jul 24SellUS$257,888Peter SalzmannIndividual8,685US$30.55
17 Jul 24SellUS$85,132Julia ButchkoIndividual2,867US$30.55
17 Jul 24SellUS$92,733Eva BarnettIndividual3,123US$30.55
17 Jul 24SellUS$90,386William MaciasIndividual3,044US$30.55
17 Jul 24SellUS$74,382Mark LevineIndividual2,505US$30.55
09 Jul 24SellUS$129,609Peter SalzmannIndividual4,619US$28.06
09 Jul 24SellUS$42,848Julia ButchkoIndividual1,527US$28.06
09 Jul 24SellUS$133,201Eva BarnettIndividual4,747US$28.06
22 May 24SellUS$96,125Mark LevineIndividual3,242US$29.65
22 May 24SellUS$96,274William MaciasIndividual3,247US$29.65
22 May 24SellUS$96,274Julia ButchkoIndividual3,247US$29.65
22 May 24SellUS$479,233Peter SalzmannIndividual16,163US$29.65
22 May 24SellUS$119,845Eva BarnettIndividual4,042US$29.65
24 Apr 24SellUS$114,531Mark LevineIndividual3,963US$28.90
24 Apr 24SellUS$94,243Michael GeffnerIndividual3,261US$28.90
24 Apr 24SellUS$209,207Jay StoutIndividual7,239US$28.90
17 Apr 24SellUS$990,269Peter SalzmannIndividual34,079US$29.94
17 Apr 24SellUS$293,923Julia ButchkoIndividual10,115US$29.94
17 Apr 24SellUS$285,554Mark LevineIndividual9,827US$29.94
17 Apr 24SellUS$356,049Eva BarnettIndividual12,253US$29.94
17 Apr 24SellUS$240,602William MaciasIndividual8,280US$29.94
09 Apr 24SellUS$149,882Peter SalzmannIndividual4,807US$31.18
09 Apr 24SellUS$115,023Eva BarnettIndividual3,689US$31.18
09 Apr 24SellUS$32,833Julia ButchkoIndividual1,053US$31.18
22 Feb 24SellUS$486,362Peter SalzmannIndividual13,454US$36.15
22 Feb 24SellUS$77,144Mark LevineIndividual2,134US$36.15
22 Feb 24SellUS$77,578Julia ButchkoIndividual2,146US$36.15
22 Feb 24SellUS$80,289William MaciasIndividual2,221US$36.15
22 Feb 24SellUS$105,920Eva BarnettIndividual2,930US$36.15
26 Jan 24SellUS$114,778Mark LevineIndividual3,027US$38.45
26 Jan 24SellUS$383,012Michael GeffnerIndividual10,101US$38.45
18 Jan 24SellUS$17,397William MaciasIndividual424US$41.03
11 Jan 24SellUS$147,023Eva BarnettIndividual3,515US$42.43
05 Jan 24SellUS$147,568Peter SalzmannIndividual3,824US$38.59
05 Jan 24SellUS$50,051Julia ButchkoIndividual1,297US$38.59

Insider Trading Volume

Insider Buying: IMVT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IMVT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,317,3390.82%
Institutions79,591,29449.5%
Public Companies79,805,33149.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 96.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
54.4%
Roivant Sciences Ltd.
79,805,331US$2.0b0%no data
8.54%
FMR LLC
12,537,561US$307.0m19.6%0.02%
4.54%
The Vanguard Group, Inc.
6,658,800US$163.1m2.29%no data
3.44%
BlackRock, Inc.
5,053,150US$123.8m2.79%no data
3.09%
T. Rowe Price Group, Inc.
4,540,063US$111.2m52%0.01%
2.96%
Deep Track Capital, LP
4,347,464US$106.5m50.8%3.42%
2.42%
Armistice Capital LLC
3,548,000US$86.9m4.45%2.14%
2.06%
State Street Global Advisors, Inc.
3,022,342US$74.0m11.2%no data
1.62%
Perceptive Advisors LLC
2,378,762US$58.3m23.7%1.41%
1.58%
Viking Global Investors LP
2,320,902US$56.8m0%0.2%
1.28%
Alpine Global Management, LLC
1,882,704US$46.1m-1.31%12.68%
1.03%
Geode Capital Management, LLC
1,510,926US$37.0m6.85%no data
0.96%
Woodline Partners LP
1,414,977US$34.7m-22.4%0.32%
0.93%
Paradigm Biocapital Advisors LP
1,362,827US$33.4m0%1.28%
0.84%
Pictet Asset Management Limited
1,230,309US$30.1m4.72%0.03%
0.83%
Baker Bros. Advisors LP
1,225,410US$30.0m164%0.31%
0.83%
Rock Springs Capital Management LP
1,221,309US$29.9m3.01%1.06%
0.78%
Hood River Capital Management LLC
1,143,567US$28.0m0%0.44%
0.77%
ADAR1 Capital Management, LLC
1,131,707US$27.7m137%5.35%
0.75%
Logos Global Management, L.P.
1,100,000US$26.9m91.3%3.45%
0.69%
Franklin Resources, Inc.
1,017,396US$24.9m-1.55%0.01%
0.67%
Capital Research and Management Company
976,237US$23.9m0%no data
0.65%
Principal Global Investors, LLC
951,124US$23.3m69.9%0.01%
0.58%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
856,567US$21.0m-0.97%0.01%
0.56%
Tavistock Life Sciences
825,000US$20.2m0%1.46%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 16:52
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunovant, Inc. is covered by 17 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason Matthew GerberryBofA Global Research
Louise ChenCantor Fitzgerald & Co.